Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gross Margin for 4 consecutive years, with 99.84% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 2276.0% to 99.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 99.43% through Dec 2025, up 717.0% year-over-year, with the annual reading at 99.43% for FY2025, 717.0% up from the prior year.
  • Gross Margin for Q4 2025 was 99.84% at Orchestra BioMed Holdings, up from 94.31% in the prior quarter.
  • The five-year high for Gross Margin was 99.84% in Q4 2025, with the low at 77.08% in Q4 2024.
  • Average Gross Margin over 4 years is 92.24%, with a median of 94.42% recorded in 2024.
  • The sharpest move saw Gross Margin crashed -1313bps in 2023, then surged 2276bps in 2025.
  • Over 4 years, Gross Margin stood at 95.19% in 2022, then dropped by -14bps to 82.06% in 2023, then dropped by -6bps to 77.08% in 2024, then increased by 30bps to 99.84% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 99.84%, 94.31%, and 94.5% for Q4 2025, Q3 2025, and Q2 2025 respectively.